Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASCO 2019 /
Clinical activity and tolerability of the RET inhibitor BLUE-667 in patients with advanced RET fusion and NSCLC

31st May - 4th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 06.06.19
Views: 470
Rating:

Dr Justin F. Gainor - Massachusetts General Hospital, Boston, USA

Dr Justin F. Gainor talks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about the results from a study examining the clinical activity and tolerability of the RET inhibitor BLUE-667 in patients with advanced RET fusion and NSCLC.

He explains that 120 patients were included for the safety portion and it was seen that BLUE-667 was well tolerated mostly grade 1 and 2 side effects.

Dr Gainor reports that promising activity was seen in patients with RET fusion positive NSCLC and within the subset of 48 patients with valuable disease there was an overall response rate of 58%.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation